Search Results
Mar 09, 2026, 08:01 ET Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful,
More news about: Acurx Pharmaceuticals, Inc.
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
bispecific antibody portfolios.We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of our drug candidates, coupled with our global perspectives, proactive strategy,
More news about: Leads Biolabs
Mar 05, 2026, 13:31 ET Fapon Biopharma présente la plateforme CD3/TCR VHH TCE de nouvelle génération au cours du 19e Forum européen annuel des PDG des sciences de la vie
ainsi qu'une pharmacocinétique et une pharmacodynamique prévisibles dans des études sur des souris et des primates non-humains.Avec des profils CMC supérieurs et une flexibilité pour le formatage multivalent, Fapon Biopharma recherche des partenaires stratégiques pour le co-développement et l'octroi
More news about: Fapon Biopharma
Mar 05, 2026, 01:24 ET Fapon Biopharma präsentiert CD3/TCR VHH TCE-Plattform der nächsten Generation auf dem 19. Annual European Life Sciences CEO Forum
Wirksamkeit und Sicherheit sowie eine vorhersagbare PK/PD in Studien mit Mäusen und NHP gezeigt.Fapon Biopharma verfügt über ein hervorragendes CMC-Profil und Flexibilität bei der Formatierung von mehrwertigen Produkten und ist auf der Suche nach strategischen Partnern für die gemeinsame Entwicklung
More news about: Fapon Biopharma
Mar 05, 2026, 01:24 ET Fapon Biopharma presentará la plataforma CD3/TCR VHH TCE de próxima generación
éxito la evaluación, demostrando una eficacia y seguridad superiores, así como una FC/FD predecible en estudios con ratones y NHP.Con perfiles de CMC superiores y flexibilidad para formatos multivalentes, Fapon Biopharma busca socios estratégicos para el desarrollo conjunto y la concesión de licencias.
More news about: Fapon Biopharma
Mar 04, 2026, 10:27 ET Frontage Laboratories Completes Acquisition of Teddy Lab, Strengthening Global Central Laboratory Capabilities
integrating Teddy Lab's central laboratory expertise with Frontage's comprehensive service platform – including bioanalytical, DMPK, safety and toxicology, CMC, and clinical trial support – Frontage hopes to further solidify its position as a trusted partner in the clinical research industry.The acquisition
More news about: Frontage Laboratories, Inc.
Mar 04, 2026, 02:00 ET Fapon Biopharma to Present Next-Generation CD3/TCR VHH TCE Platform at 19th Annual European Life Sciences CEO Forum
successfully completed evaluation demonstrating superior efficacy and safety as well as predictable PK/PD in mouse and NHP studies.With superior CMC profiles and flexibility for multi-valent formatting, Fapon Biopharma is seeking strategic partners for co-development and licensing. For partnership
More news about: Fapon Biopharma
Mar 03, 2026, 09:30 ET Get to Know Africa: A $9 Billion U.S.-Backed Minerals Deal Could Reshape Western Access to Congo's Cobalt. One Treasury Decision Stands in the Way
implications for U.S. clean energy infrastructure, electric vehicle manufacturing, and national defense.The Orion Critical Minerals Consortium (Orion CMC), backed by the U.S. International Development Finance Corporation (DFC), represents a serious, government-supported effort to change that equation. Deputy
More news about: Get to Know Africa
Feb 27, 2026, 09:19 ET Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
(PRKAG2 syndrome): Investigational New Drug (IND)-enabling studies and CMC manufacturing underway. Atrium expects to file an IND in the second half of 2026.ATR 1086 (PLN cardiomyopathy): Chemistry Manufacturing and Controls (CMC) manufacturing planned to support initiation of IND-enabling preclinical
More news about: Atrium Therapeutics
Feb 27, 2026, 04:11 ET WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
products.Leveraging its world-leading integrated CRDMO platform, WuXi XDC will also fully support the Chemical, Manufacturing, and Controls (CMC) development and manufacturing of the ADC components within the collaboration. Earendil Labs will focus on subsequent product development, global regulatory
More news about: WuXi XDC
Feb 27, 2026, 02:00 ET Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
products.Leveraging its world-leading integrated CRDMO platform, WuXi XDC will also fully support the Chemical, Manufacturing, and Controls (CMC) development and manufacturing of the ADC components within the collaboration. Earendil Labs will focus on subsequent product development, global regulatory
More news about: Earendil Labs
Feb 26, 2026, 16:15 ET CMC Announces Second Quarter Fiscal 2026 Conference Call Webcast Details
www.cmc.com. About CMCCMC is a Fortune 500 company (NYSE: CMC) headquartered in Irving, Texas, and a leading provider of early-stage construction solutions that support the foundational phases of modern infrastructure and building projects. Founded in 1915, CMC has grown from a single-site
More news about: CMC
Feb 26, 2026, 07:55 ET KOPPERS REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS; PROVIDES 2026 OUTLOOK
Adjusted EBITDA was slightly lower due to lower sales volumes, partly offset by lower raw material and logistics costs and higher royalty income.CMC net sales decreased mainly due to $16.6 million in volume decreases of phthalic anhydride as the company discontinued production, lower volumes and lower
More news about: KOPPERS HOLDINGS INC.
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) 獲得 POLTX_Fiber™ 的 CE 標誌認證：APT™ 技術首度應用，為傷口護理樹立全新標準
POLTX_Fiber™ 是該公司首款產品：一種結合創新APT™技術的抗菌凝膠纖維敷料。此重大時刻標誌著寶麗來治療公司正式進軍傷口護理領域，目標是透過 APT™ 平台為傷口護理樹立全新標準。 POLTX_Fiber™ 是一款柔軟、可塑性的無紡布敷料，由羧甲基纖維素鈉 (CMC) 纖維與強化纖維素纖維製成，並整合了新開發的 APT™ 技術。當敷料接觸傷口滲出液時，APT™ 技術能防止細菌在敷料內定殖，同時不會助長抗微生物藥物抗藥性的產生。敷料吸收滲出液後形成凝膠，有助維持濕潤的傷口環境，促進自溶性清創作用，並改善傷口邊緣及周邊皮膚因浸軟造成的損傷。在醫療保健專業人員的監督下，POLTX_Fiber™
More news about: Polaroid Therapeutics
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) erhält das CE-Zeichen für POLTX-Fiber™: die erste Anwendung von APT™ zur Einführung eines neuen Standards in der Wundversorgung
Standard in der Wundversorgung zu setzen. POLTX-Fiber™ ist ein weicher, anpassungsfähiger Vliesstoffverband aus Natriumcarboxymethylcellulose (CMC)-Fasern und verstärkenden Cellulosefasern, in den das neu entwickelte APT™ integriert ist. Wenn der Verband mit Wundexsudat in Berührung kommt, verhindert
More news about: Polaroid Therapeutics
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber™: the first application of APT™ to launch a new standard in wound care
POLTX_Fiber™ is a soft, conformable non-woven dressing made of sodium carboxymethylcellulose (CMC) fibers and strengthening cellulose fibers that integrates the newly developed APT™. When the dressing is in contact with wound exudate, APT™ prevents
More news about: Polaroid Therapeutics
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber™: the first application of APT™ to launch a new standard in wound care
in wound care through the APT™ platform. POLTX_Fiber™ is a soft, conformable non-woven dressing made of sodium carboxymethylcellulose (CMC) fibers and strengthening cellulose fibers that integrates the newly developed APT™. When the dressing is in contact with wound exudate, APT™ prevents
More news about: Polaroid Therapeutics
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) recibe la marca CE para POLTX_Fiber™: la primera aplicación de APT™ que establece un nuevo estándar en el cuidado de heridas
de heridas a través de la plataforma APT™. POLTX_Fiber™ es un vendaje suave y adaptable, fabricado con fibras de carboximetilcelulosa sódica (CMC) y fibras de celulosa reforzadas que integra la tecnología APT™ recientemente desarrollada. Cuando el vendaje entra en contacto con la exudación de la
More news about: Polaroid Therapeutics
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) recebe a marcação CE para POLTX_Fiber™: a primeira aplicação da tecnologia APT™ a lançar um novo padrão no tratamento de feridas
feridas por meio da plataforma APT™. O POLTX_Fiber™ é um curativo não tecido macio e adaptável, feito de fibras de carboximetilcelulose sódica (CMC) e de fibras de celulose de reforço, que integra a tecnologia APT™ recém-desenvolvida. Quando o curativo entra em contato com o exsudato da ferida, a
More news about: Polaroid Therapeutics
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) recibe la marca CE para POLTX_Fiber™
heridas a través de la plataforma APT™.POLTX_Fiber™ es un apósito no tejido suave y adaptable, hecho de fibras de carboximetilcelulosa sódica (CMC) y fibras de celulosa fortalecedoras que integra la nueva tecnología APT™. Cuando el apósito entra en contacto con el exudado de la herida, APT™ previene
More news about: Polaroid Therapeutics
Feb 25, 2026, 03:30 ET Polaroid Therapeutics (PTx) reçoit le marquage CE pour POLTX_Fiber™ : la première application de l'APT™ pour lancer une nouvelle norme dans le traitement des plaies
grâce à la plateforme APT™. POLTX_Fiber™ est un pansement non tissé souple et conformable composé de fibres de carboxyméthylcellulose sodique (CMC) et de fibres de cellulose renforçantes qui intègrent l'APT™ nouvellement développé. Lorsque le pansement est en contact avec l'exsudat de la plaie,
More news about: Polaroid Therapeutics
Feb 24, 2026, 09:02 ET Beer Girl Builds National Momentum with Multi-State Expansion and Strategic Leadership Addition
Countermeasures (CMC) to drive growth in targeted U.S. markets and expand its presence across key national accounts."The team at Beer Girl has done an exceptional
More news about: Beer Girl Brewing Co
Feb 23, 2026, 08:00 ET iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
(FTD) and Regenerative Medicine Advanced Therapy (RMAT) designation. This progression validates iRegene's preclinical and clinical package and robust CMC framework, enabling closer FDA collaboration and accelerated pathways.NouvNeu001 is designed to address the underlying pathology of Parkinson's
More news about: iRegene Therapeutics Co., Ltd.
Feb 17, 2026, 09:00 ET Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
validated for inclusion in the Chemistry, Manufacturing and Controls (CMC) section of Thykamine™ production.Collectively, the HPLC-MS fingerprinting, NMR confirmation, and potency assays will form an integral part of Devonian's CMC framework for Thykamine™ production, reinforcing
More news about: Devonian Health Group Inc.
Feb 17, 2026, 06:00 ET IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
payment under the license agreement for IDE849 with Hengrui Pharma during the three months ended December 31, 2024, offset by higher clinical trial and CMC manufacturing expenses to support our programs and personnel-related expenses during the three months ended December 31, 2025.General and administrative
More news about: IDEAYA Biosciences, Inc.